| __timestamp | Catalyst Pharmaceuticals, Inc. | TG Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 10117774 | 31354781 |
| Thursday, January 1, 2015 | 11801342 | 43445817 |
| Friday, January 1, 2016 | 11369941 | 66489820 |
| Sunday, January 1, 2017 | 11375237 | 96886134 |
| Monday, January 1, 2018 | 19919204 | 153793000 |
| Tuesday, January 1, 2019 | 18842752 | 148369000 |
| Wednesday, January 1, 2020 | 16496715 | 151934000 |
| Friday, January 1, 2021 | 16936000 | 198532000 |
| Saturday, January 1, 2022 | 19789000 | 112128000 |
| Sunday, January 1, 2023 | 93150000 | 76192000 |
Unleashing insights
In the competitive world of biotechnology, research and development (R&D) spending is a critical indicator of a company's commitment to innovation. Over the past decade, TG Therapeutics, Inc. and Catalyst Pharmaceuticals, Inc. have demonstrated contrasting strategies in their R&D investments. From 2014 to 2023, TG Therapeutics consistently outspent Catalyst Pharmaceuticals, with its R&D expenses peaking at nearly 200% higher than Catalyst's in 2018. However, in 2023, Catalyst Pharmaceuticals made a significant leap, increasing its R&D spending by over 370% compared to 2022, surpassing TG Therapeutics for the first time in this period. This shift highlights Catalyst's intensified focus on innovation, potentially signaling a strategic pivot. As these companies continue to navigate the dynamic biotech landscape, their R&D investments will likely play a pivotal role in shaping their future success.
Comparing Innovation Spending: Eli Lilly and Company and TG Therapeutics, Inc.
Research and Development: Comparing Key Metrics for Novo Nordisk A/S and TG Therapeutics, Inc.
Comparing Innovation Spending: Bristol-Myers Squibb Company and Catalyst Pharmaceuticals, Inc.
Vertex Pharmaceuticals Incorporated vs Catalyst Pharmaceuticals, Inc.: Strategic Focus on R&D Spending
Comparing Innovation Spending: GSK plc and Catalyst Pharmaceuticals, Inc.
Research and Development: Comparing Key Metrics for Takeda Pharmaceutical Company Limited and TG Therapeutics, Inc.
R&D Spending Showdown: Genmab A/S vs TG Therapeutics, Inc.
BioMarin Pharmaceutical Inc. vs TG Therapeutics, Inc.: Strategic Focus on R&D Spending
Research and Development: Comparing Key Metrics for Lantheus Holdings, Inc. and Catalyst Pharmaceuticals, Inc.
Research and Development: Comparing Key Metrics for Axsome Therapeutics, Inc. and TG Therapeutics, Inc.
R&D Spending Showdown: Catalyst Pharmaceuticals, Inc. vs Iovance Biotherapeutics, Inc.
R&D Insights: How Catalyst Pharmaceuticals, Inc. and MannKind Corporation Allocate Funds